Erschienen: 30.10.2012 Abbildung von Progress in Drug Research | 2012 | 55

Progress in Drug Research

lieferbar ca. 10 Tage als Sonderdruck ohne Rückgaberecht

2012. Buch. vIII, 336 S. Bibliographien. Softcover

Birkhäuser. ISBN 978-3-0348-9544-6

Format (B x L): 17,8 x 25,4 cm

Gewicht: 662 g

In englischer Sprache

Das Werk ist Teil der Reihe: Progress in Drug Research; 55


Hepatitis C virus (HCV) was first identified in 1989 as the etiologic agent of non-A, non-B hepatitis [1] and is currently recognized as the leading cause of chronic liver disease worldwide. In contrast to hepatitis B virus infection, in which only about 5% of adult infections become chronic, more than 80% of HCV-infected patients develop chronic hepatitis. Moreover, 20-50% of those persistently infected with HCV will develop liver cirrhosis and hepatocellu­ lar carcinoma (HCC) [2]. It is estimated that there are 10,000 deaths in the USA per year due to chronic liver failure or HCC [3]. In addition, HCV dis­ 25-50% of all liver transplants in US centers, and the ease is responsible for recurrence of HCV infection following liver transplantation is universal [4]. Typically, HCV disease emerges after a 10-20 year period during which symp­ toms, if they exist at all, are mild and non-specific. Although the prevalence varies greatly among different countries, it has been estimated that up to 170 million people (3% of the world's population), are infected with HCV [5]. A recent study in the USA found that 65% of all HCV-infected persons are 30 to 49 years old [6].


  • Dieses Set enthält folgende Produkte:
      Auch in folgendem Set erhältlich:
      • nach oben

        Ihre Daten werden geladen ...